Epstein-Barr Virus nuclear protein EBNA3A is critical for maintaining lymphoblastoid cell line growth.
To evaluate the role of Epstein-Barr Virus (EBV) nuclear antigen 3A (EBNA3A) in the continuous proliferation of EBV-infected primary B lymphocytes as lymphoblastoid cell lines (LCLs), we derived LCLs that are infected with a recombinant EBV genome that expresses EBNA3A fused to a 4-hydroxy-tamoxifen (4HT)-dependent mutant estrogen receptor hormone binding domain (EBNA3AHT). The LCLs grew similarly to wild-type LCLs in medium with 4HT despite a reduced level of EBNA3AHT fusion protein expression. In the absence of 4HT, EBNA3AHT moved from the nucleus to the cytoplasm and was degraded. EBNA3AHT-infected LCLs were unable to grow in medium without 4HT. The precise time to growth arrest varied inversely with cell density. Continued maintenance in medium without 4HT resulted in cell death, whereas readdition of 4HT restored cell growth. Expression of other EBNAs and LMP1, of CD23, and of c-myc was unaffected by EBNA3A inactivation. Wild-type EBNA3A expression from an oriP plasmid transfected into the LCLs protected the EBNA3AHT-infected LCLs from growth arrest and death in medium without 4HT, whereas EBNA3B or EBNA3C expression was unable to protect the LCLs from growth arrest and death. These experiments indicate that EBNA3A has a unique and critical role for the maintenance of LCL growth and ultimately survival. The EBNA3AHT-infected LCLs are also useful for genetic and biochemical analyses of the role of EBNA3A domains in LCL growth.
Maruo
Seiji
S
Department of Medicine and Microbiology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.
Johannsen
Eric
E
Illanes
Diego
D
Cooper
Andrew
A
Kieff
Elliott
E
D001402:B-Lymphocytes / Q000502:physiology* / Q000821:virology*; D002455:Cell Division / Q000502:physiology*; D019309:Epstein-Barr Virus Nuclear Antigens / Q000502:physiology*; D004854:Herpesvirus 4, Human / Q000235:genetics*; D006801:Humans; D016271:Proto-Oncogene Proteins c-myc / Q000032:analysis; D017464:Receptors, Complement 3d / Q000032:analysis; D017455:Receptors, IgE / Q000032:analysis; D011995:Recombination, Genetic; D013629:Tamoxifen / Q000031:analogs & derivatives* / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D014763:Viral Matrix Proteins / Q000032:analysis
C037662:EBV-associated membrane antigen, Epstein-Barr virus; D019309:Epstein-Barr Virus Nuclear Antigens; D016271:Proto-Oncogene Proteins c-myc; D017464:Receptors, Complement 3d; D017455:Receptors, IgE; D014763:Viral Matrix Proteins; D013629:Tamoxifen; C016601:afimoxifene